Does Biopharmx Corporation (NYSEMKT:BPMX) Have Gas After Even Less Sellers Involved?

September 17, 2017 - By Richard Conner

 Does Biopharmx Corporation (NYSEMKT:BPMX) Have Gas After Even Less Sellers Involved?

The stock of Biopharmx Corporation (NYSEMKT:BPMX) registered a decrease of 2.93% in short interest. BPMX’s total short interest was 4.31 million shares in September as published by FINRA. Its down 2.93% from 4.44M shares, reported previously. With 532,900 shares average volume, it will take short sellers 8 days to cover their BPMX’s short positions. The short interest to Biopharmx Corporation’s float is 10.75%.

The stock increased 6.09% or $0.018 on September 15, reaching $0.305. About 542,089 shares traded. Biopharmx Corp (NYSEMKT:BPMX) has declined 5.75% since September 17, 2016 and is downtrending. It has underperformed by 22.45% the S&P500.

BioPharmX Corporation is a specialty pharmaceutical company. The company has market cap of $24.30 million. The Firm is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter products that address markets in women’s health and dermatology. It currently has negative earnings. The Company’s portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Biopharmx Corp (NYSEMKT:BPMX) Ratings Coverage

Among 5 analysts covering BioPharmX Corporation (NYSEMKT:BPMX), 4 have Buy rating, 1 Sell and 0 Hold. Therefore 80% are positive. BioPharmX Corporation had 5 analyst reports since September 4, 2015 according to SRatingsIntel. ValuEngine upgraded Biopharmx Corp (NYSEMKT:BPMX) on Thursday, May 25 to “Sell” rating. H.C. Wainwright maintained it with “Buy” rating and $3 target in Friday, May 5 report. Roth Capital maintained Biopharmx Corp (NYSEMKT:BPMX) on Friday, May 5 with “Buy” rating. On Friday, May 5 the stock rating was maintained by Maxim Group with “Buy”. The rating was initiated by Sterne Agee CRT with “Buy” on Friday, September 4.

More notable recent Biopharmx Corp (NYSEMKT:BPMX) news were published by: Benzinga.com which released: “BioPharmX CFO Talks Clinical Pipeline Ahead Of Big Q2 Catalyst” on March 31, 2017, also Prnewswire.com with their article: “BioPharmX Reports First Quarter 2018 Financial Results” published on June 13, 2017, Seekingalpha.com published: “BioPharmX Has A Major Upcoming Catalyst” on March 27, 2017. More interesting news about Biopharmx Corp (NYSEMKT:BPMX) were released by: Prnewswire.com and their article: “BioPharmX Corporation Announces Pricing of Unit Offering” published on November 22, 2016 as well as Seekingalpha.com‘s news article titled: “BioPharmX Pivot Means It’s Time To Wait” with publication date: November 22, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.